FORM 4

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
Section 16. Form 4 or Form 5		
obligations may continue. See		

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hoang Peter L.					2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [BLCM]						C (Cr	eck all appli Directo	or (give title		son(s) to Issuer 10% Owner Other (specify below)	
(Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800			0	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2017							Sr. V	Sr. VP of Bus. Development				
(Street) HOUST(IOUSTON TX 77030			4	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check AppLine) X Form filed by One Reporting Persor Form filed by More than One Reporting Person						ı					
1. Title of Security (Instr. 3) 2. Transa Date				Transaction	action 2A. Deemed Execution Date,		Code (Instr. 5)		ed (A) or	5. Amou	int of es ially	Form	: Direct c	7. Nature of Indirect Beneficial Ownership		
				(Code V	Amount	(A) o	r Price	Reported Transact (Instr. 3	d tion(s)	(,, (,		(Instr. 4)		
			Table II - De (e.					uired, Dis , options,				Owned				
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution I or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date if any (Month/Day/Ye	Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
				Code	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$13.89	01/03/2017		A		11,250		(1)	01/02/2027	Common Stock	11,250	\$0	11,250	0	D	
Restricted Stock	(2)	01/03/2017		A		6,250		(3)	(3)	Common	6,250	\$0	6,250	,	D	

Explanation of Responses:

- 1. 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of BLCM common stock.
- 3. The restricted stock units vest in four equal annual installments beginning January 3, 2018.

Remarks:

/s/ Peter L. Hoang

01/05/2017

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.